Emulsion based vaccine adjuvants

O’Hagan, Derek T.; Tsai, T. F.; Brito, Luis A.

doi:10.4161/hv.24829

Cited by 13 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SAM-NPs induced a similar phenotype in CD8 + T-cells to Rabipur, however, the quality of released cytokines was different. This finding correlated with the observed cytotoxic profile and was in line with what has been already documented in the literature [ 19 , 39 , 54 , 92 ]. Overall, results reported here showed differences in quantity rather than quality of cytokines proliferation induced by the SAM-loaded candidates tested, with NPs eliciting higher CD4 + and CD8 + cytokines release compared to both liposomes.…”

Section: Discussionsupporting

confidence: 92%

“…To date, cationic liposomes have been applied in more than 100 clinical trials, mainly for cancer therapy and monogenic diseases like cystic fibrosis [ 52 ]. Nanoemulsions have also been described as a means to improve transfection of nucleic acids and they have been evaluated in humans for a range of vaccine candidates, including those targeting herpes simplex virus (HSV), human immunodeficiency virus (HIV), hepatitis C virus (HCV) and cytomegalovirus (CMV) [ 53 , 54 , 55 ]. More recently, a cationic version of the squalene-based emulsion-MF59, which contains the cationic lipid DOTAP- has been used to potentiate the immune response of a SAM in both rabbits and non-human primates (NHP) [ 39 ], and recently entered a phase I clinical trial.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

Anderluzzi

Lou

Gallorini³

et al. 2020

Vaccines

View full text Add to dashboard Cite

messenger RNA (mRNA)-based vaccines combine the positive attributes of both live-attenuated and subunit vaccines. In order for these to be applied for clinical use, they require to be formulated with delivery systems. However, there are limited in vivo studies which compare different delivery platforms. Therefore, we have compared four different cationic platforms: (1) liposomes, (2) solid lipid nanoparticles (SLNs), (3) polymeric nanoparticles (NPs) and (4) emulsions, to deliver a self-amplifying mRNA (SAM) vaccine. All formulations contained either the non-ionizable cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or dimethyldioctadecylammonium bromide (DDA) and they were characterized in terms of physico-chemical attributes, in vitro transfection efficiency and in vivo vaccine potency. Our results showed that SAM encapsulating DOTAP polymeric nanoparticles, DOTAP liposomes and DDA liposomes induced the highest antigen expression in vitro and, from these, DOTAP polymeric nanoparticles were the most potent in triggering humoral and cellular immunity among candidates in vivo.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

Anderluzzi

Lou

Gallorini³

et al. 2020

Vaccines

View full text Add to dashboard Cite

show abstract

“…More work is needed to elucidate how Th2-biased immune responses are induced by Alum-adjuvanted vaccines [ 83 , 84 ]. Alum adjuvant remained the only adjuvant for more than half a century until squalene emulsion-based MF59 adjuvant was approved by European Authorities in 1997 to enhance seasonal influenza vaccine efficacy in the elderly [ 85 , 86 , 87 ]. MF59 was approved in 2015 to enhance seasonal influenza vaccine efficacy in the elderly in the United States [ 88 , 89 ].…”

Section: Vaccine Adjuvantsmentioning

confidence: 99%

Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity

Zhao

et al. 2021

Vaccines

View full text Add to dashboard Cite

Influenza poses a huge threat to global public health. Influenza vaccines are the most effective and cost-effective means to control influenza. Current influenza vaccines mainly induce neutralizing antibodies against highly variable globular head of hemagglutinin and lack cross-protection. Vaccine adjuvants have been approved to enhance seasonal influenza vaccine efficacy in the elderly and spare influenza vaccine doses. Clinical studies found that MF59 and AS03-adjuvanted influenza vaccines could induce cross-protective immunity against non-vaccine viral strains. In addition to MF59 and AS03 adjuvants, experimental adjuvants, such as Toll-like receptor agonists, saponin-based adjuvants, cholera toxin and heat-labile enterotoxin-based mucosal adjuvants, and physical adjuvants, are also able to broaden influenza vaccine-induced immune responses against non-vaccine strains. This review focuses on introducing the various types of adjuvants capable of assisting current influenza vaccines to induce cross-protective immunity in preclinical and clinical studies. Mechanisms of licensed MF59 and AS03 adjuvants to induce cross-protective immunity are also introduced. Vaccine adjuvants hold a great promise to adjuvant influenza vaccines to induce cross-protective immunity.

show abstract

“…Prva generacija vakcina sa emulzijama kao adjuvansima imala je u svom sastavu mineralna ulja koja se nisu mogla metabolisati, i iako su bila snažni aktivatori produkcije antitela, uzrokovala su nastanak apscesa (39). Razvojem emulzija tipa ulje-u-vodi, poput MF59 i adjuvantnog sistema AS03, u kojima se koristi mineralno ulje koje se u potpunosti metaboliše, prevaziđen je problem prethodno korišćenih emulzija i omogućena je primena adjuvanasa na bazi emulzije u inaktivisanoj vakcini protiv sezonskog gripa, zatim u vakcini protiv ptičjeg gripa (H5N1, a kasnije i drugih sojeva) i u vakcini protiv pandemijskog gripa 2009. godine (H1N1) (40).…”

Section: Adjuvansi Na Bazi Emulzije: Mf59 I As03unclassified

Adjuvants in vaccines registered for human use

Filipić¹,

Stojić-Vukanić²

2019

Arhiv za farmaciju

View full text Add to dashboard Cite

Vakcinacija je jedna od najznačajnijih strategija za prevenciju infektivnih oboljenja, a razvoj subjediničnih vakcina doveo je do potrebe za primenom adjuvanasa u vakcinama. Naziv adjuvans potiče od latinske reči adjuvare što znači "pomoći". Adjuvansi su supstance koje se primenjuju u vakcinama više od 90 godina, a dodaju se da bi se povećala imunogenost antigena koji imaju nizak imunostimulatorni potencijal. U vakcinama za primenu kod ljudi, najduže se kao adjuvansi koriste soli aluminijuma, ali je poslednjih decenija nekoliko novih adjuvanasa uključeno u vakcine koje su odobrene za primenu. Adjuvantni sistem AS04, ulazi u sastav vakcina protiv humanog papiloma virusa (Cervarix ®) i hepatitis B virusa (Fendrix ®) i sadrži aluminijum hidroksid i TLR4 agonist, monofosforil lipid A. Zatim, adjuvansi na bazi emulzije (MF59 i AS03) su sastavni deo vakcina protiv gripa (Fluad ® , Focetria ® i Pandemrix ®). Kombinacija dva imunostimulatorna molekula, označena kao AS01, ulazi u sastav vakcine protiv herpes zoster virusa i malarije dok se adjuvansi na bazi virozoma koriste u vakcinama protiv hepatitisa A (Epaxal ®) i gripa (Inflexal ® V, Invivac ®). Daljim razvojem adjuvanasa, i ispitivanjem njihovog mehanizma delovanja oni će se umesto empirijski, sve više koristili racionalno i ciljano, čime će se postići bolji imunogeni profil vakcina, bez narušavanja njihovog bezbednosnog profila.

show abstract

Emulsion based vaccine adjuvants

Cited by 13 publications

References 7 publications

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity

Adjuvants in vaccines registered for human use

Contact Info

Product

Resources

About